EyePoint, Inc.
DE ˙ DB ˙ US30233G2093
10,10 € ↓ -0,30 (-2,88%)
2026-06-04
AKTIENPREIS
SecurityDE:PV3B / EyePoint, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership75,336 shares
Latest Disclosed Value $ 1,376,389
Alliancebernstein L.p. reports 0.33% increase in ownership of PV3B / EyePoint, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 75,336 shares of EyePoint, Inc. (DE:PV3B) valued at $753,737 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 75,090 shares of EyePoint, Inc.. This represents a change in shares of 0.33% during the quarter. The current value of the position is $760,894 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F EYEPOINT COM NEW 30233G209 75,336 246 0.33 1,376 0.36 0.0004
2026-02-17 2025-12-31 13F EYEPOINT COM NEW 30233G209 75,090 16,500 28.16 1,372 64.39 0.0004
2025-11-14 2025-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 58,590 0 0.00 834 51.36 0.0003
2025-08-14 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 58,590 7,700 15.13 551 100.36 0.0002
2025-05-15 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 50,890 7,100 16.21 276 -15.64 0.0001
2025-02-12 2024-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 43,790 0 0.00 326 -6.59 0.0001
2024-11-14 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 43,790 -7,970 -15.40 350 -22.44 0.0001
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 51,760 24,160 87.54 450 -21.05 0.0002
2024-05-14 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 27,600 5,000 22.12 570 9.20 0.0002
2024-02-14 2023-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 22,600 2,780 14.03 522 230.38 0.0002
2023-11-14 2023-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 19,820 5,040 34.10 158 23.44 0.0001
2023-08-15 2023-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 14,780 14,780 129 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.